Cowen defended WebMD (WBMD) on yesterday's weakness, which it attributes to Google's (GOOG) symptom tracker release. The firm sees minimal impact on WebMD since Google offers a more targeted search but not real clinical content. Cowen also noted WebMD's core business is tied to the physician market and a significant portion of WebMD's revenues come from drug sales. The firm reiterated its Outperform rating and $70 price target on WebMD shares, which fell about 2% yesterday to close at $60.84.
Welcome to "#SocialStocks," The Fly's weekly recap of Wall Street's reactions to social media stock news. GOVERNMENT SCRUTINY: The Biden... To see the rest of the story go to thefly.com. See Story Here